Keywords: chiron, posts, sales, jump, flu, vacc, return
Chiron posts 12% sales jump on flu vacc return
Article | 13 February 2006
US biotechnology firm Chiron Corp says that full-year 2005 sales rose 12% year-on-year to $1.42 billion due to $96.0 million from sales of its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
